Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

NCT02429440 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT02429440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2005
Completion date
June 30, 2018
Enrollment
40 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell cancer, renal cell cancer